Video
Dr. Arkenau on Advancements on Horizon in Gastric Cancer
Author(s):
Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.
Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.
Combination regimens, such as PD-1 plus CTLA-4 agents, are currently being explored, Arkenau explains. Recent data that were presented at the 2016 ASCO Annual Meeting demonstrate promise with the management of checkpoint blockade as well as OX40 agonists, which are designed to create co-stimulatory effects on T cells.
Additional data that were presented show intriguing results of a PD-1 and OX40 combination regimen, in that it did not show any additional toxicities nor any drug-to-drug interaction, he adds.
